Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer

Zhongling Wang, Ruirui Qiao, Na Tang, Ziwei Lu, Han Wang, Zaixian Zhang, Xiangdong Xue, Zhongyi Huang, Siruo Zhang, Guixiang Zhang, Yuanpei Li

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Despite its great promise in non-invasive treatment of cancers, magnetic resonance-guided focused ultrasound surgery (MRgFUS) is currently limited by the insensitivity of magnetic resonance imaging (MRI) for visualization of small tumors, low efficiency of in vivo ultrasonic energy deposition, and damage to surrounding tissues. We hereby report the development of an active targeting nano-sized theranostic superparamagnetic iron oxide (SPIO) platform for significantly increasing the imaging sensitivity and energy deposition efficiency using a clinical MRgFUS system. The surfaces of these PEGylated SPIO nanoparticles (NPs) were decorated with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies (mAb) for targeted delivery to lung cancer with EGFR overexpression. The potential of these targeted nano-theranostic agents for MRI and MRgFUS ablation was evaluated in vitro and in vivo in a rat xenograft model of human lung cancer (H460). Compared with nontargeting PEGylated SPIO NPs, the anti-EGFR mAb targeted PEGylated SPIO NPs demonstrated better targeting capability to H460 tumor cells and greatly improved the MRI contrast at the tumor site. Meanwhile, this study showed that the targeting NPs, as synergistic agents, could significantly enhance the efficiency for in vivo ultrasonic energy deposition in MRgFUS. Moreover, we demonstrated that a series of MR methods including T2-weighted image (T2WI), T1-weighted image (T1WI), diffusion-weighted imaging (DWI) and contrast-enhanced T1WI imaging, could be utilized to noninvasively and conveniently monitor the therapeutic efficacy in rat models by MRgFUS.

Original languageEnglish (US)
Pages (from-to)25-35
Number of pages11
JournalBiomaterials
Volume127
DOIs
StatePublished - May 1 2017

Fingerprint

Magnetic resonance
Ablation
Iron oxides
Nanoparticles
Lung Neoplasms
Magnetic Resonance Spectroscopy
Ultrasonics
Magnetic Resonance Imaging
Imaging techniques
Surgery
Neoplasms
Tumors
Monoclonal antibodies
Monoclonal Antibodies
Rats
Epidermal Growth Factor Receptor
Heterografts
ferric oxide
Theranostic Nanomedicine
Therapeutics

Keywords

  • Active targeting
  • MRgFUS
  • SPIO
  • Synergistic agents

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer. / Wang, Zhongling; Qiao, Ruirui; Tang, Na; Lu, Ziwei; Wang, Han; Zhang, Zaixian; Xue, Xiangdong; Huang, Zhongyi; Zhang, Siruo; Zhang, Guixiang; Li, Yuanpei.

In: Biomaterials, Vol. 127, 01.05.2017, p. 25-35.

Research output: Contribution to journalArticle

Wang, Zhongling ; Qiao, Ruirui ; Tang, Na ; Lu, Ziwei ; Wang, Han ; Zhang, Zaixian ; Xue, Xiangdong ; Huang, Zhongyi ; Zhang, Siruo ; Zhang, Guixiang ; Li, Yuanpei. / Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer. In: Biomaterials. 2017 ; Vol. 127. pp. 25-35.
@article{6f4352750fac4518bb58048662ede6cf,
title = "Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer",
abstract = "Despite its great promise in non-invasive treatment of cancers, magnetic resonance-guided focused ultrasound surgery (MRgFUS) is currently limited by the insensitivity of magnetic resonance imaging (MRI) for visualization of small tumors, low efficiency of in vivo ultrasonic energy deposition, and damage to surrounding tissues. We hereby report the development of an active targeting nano-sized theranostic superparamagnetic iron oxide (SPIO) platform for significantly increasing the imaging sensitivity and energy deposition efficiency using a clinical MRgFUS system. The surfaces of these PEGylated SPIO nanoparticles (NPs) were decorated with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies (mAb) for targeted delivery to lung cancer with EGFR overexpression. The potential of these targeted nano-theranostic agents for MRI and MRgFUS ablation was evaluated in vitro and in vivo in a rat xenograft model of human lung cancer (H460). Compared with nontargeting PEGylated SPIO NPs, the anti-EGFR mAb targeted PEGylated SPIO NPs demonstrated better targeting capability to H460 tumor cells and greatly improved the MRI contrast at the tumor site. Meanwhile, this study showed that the targeting NPs, as synergistic agents, could significantly enhance the efficiency for in vivo ultrasonic energy deposition in MRgFUS. Moreover, we demonstrated that a series of MR methods including T2-weighted image (T2WI), T1-weighted image (T1WI), diffusion-weighted imaging (DWI) and contrast-enhanced T1WI imaging, could be utilized to noninvasively and conveniently monitor the therapeutic efficacy in rat models by MRgFUS.",
keywords = "Active targeting, MRgFUS, SPIO, Synergistic agents",
author = "Zhongling Wang and Ruirui Qiao and Na Tang and Ziwei Lu and Han Wang and Zaixian Zhang and Xiangdong Xue and Zhongyi Huang and Siruo Zhang and Guixiang Zhang and Yuanpei Li",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.biomaterials.2017.02.037",
language = "English (US)",
volume = "127",
pages = "25--35",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Active targeting theranostic iron oxide nanoparticles for MRI and magnetic resonance-guided focused ultrasound ablation of lung cancer

AU - Wang, Zhongling

AU - Qiao, Ruirui

AU - Tang, Na

AU - Lu, Ziwei

AU - Wang, Han

AU - Zhang, Zaixian

AU - Xue, Xiangdong

AU - Huang, Zhongyi

AU - Zhang, Siruo

AU - Zhang, Guixiang

AU - Li, Yuanpei

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Despite its great promise in non-invasive treatment of cancers, magnetic resonance-guided focused ultrasound surgery (MRgFUS) is currently limited by the insensitivity of magnetic resonance imaging (MRI) for visualization of small tumors, low efficiency of in vivo ultrasonic energy deposition, and damage to surrounding tissues. We hereby report the development of an active targeting nano-sized theranostic superparamagnetic iron oxide (SPIO) platform for significantly increasing the imaging sensitivity and energy deposition efficiency using a clinical MRgFUS system. The surfaces of these PEGylated SPIO nanoparticles (NPs) were decorated with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies (mAb) for targeted delivery to lung cancer with EGFR overexpression. The potential of these targeted nano-theranostic agents for MRI and MRgFUS ablation was evaluated in vitro and in vivo in a rat xenograft model of human lung cancer (H460). Compared with nontargeting PEGylated SPIO NPs, the anti-EGFR mAb targeted PEGylated SPIO NPs demonstrated better targeting capability to H460 tumor cells and greatly improved the MRI contrast at the tumor site. Meanwhile, this study showed that the targeting NPs, as synergistic agents, could significantly enhance the efficiency for in vivo ultrasonic energy deposition in MRgFUS. Moreover, we demonstrated that a series of MR methods including T2-weighted image (T2WI), T1-weighted image (T1WI), diffusion-weighted imaging (DWI) and contrast-enhanced T1WI imaging, could be utilized to noninvasively and conveniently monitor the therapeutic efficacy in rat models by MRgFUS.

AB - Despite its great promise in non-invasive treatment of cancers, magnetic resonance-guided focused ultrasound surgery (MRgFUS) is currently limited by the insensitivity of magnetic resonance imaging (MRI) for visualization of small tumors, low efficiency of in vivo ultrasonic energy deposition, and damage to surrounding tissues. We hereby report the development of an active targeting nano-sized theranostic superparamagnetic iron oxide (SPIO) platform for significantly increasing the imaging sensitivity and energy deposition efficiency using a clinical MRgFUS system. The surfaces of these PEGylated SPIO nanoparticles (NPs) were decorated with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies (mAb) for targeted delivery to lung cancer with EGFR overexpression. The potential of these targeted nano-theranostic agents for MRI and MRgFUS ablation was evaluated in vitro and in vivo in a rat xenograft model of human lung cancer (H460). Compared with nontargeting PEGylated SPIO NPs, the anti-EGFR mAb targeted PEGylated SPIO NPs demonstrated better targeting capability to H460 tumor cells and greatly improved the MRI contrast at the tumor site. Meanwhile, this study showed that the targeting NPs, as synergistic agents, could significantly enhance the efficiency for in vivo ultrasonic energy deposition in MRgFUS. Moreover, we demonstrated that a series of MR methods including T2-weighted image (T2WI), T1-weighted image (T1WI), diffusion-weighted imaging (DWI) and contrast-enhanced T1WI imaging, could be utilized to noninvasively and conveniently monitor the therapeutic efficacy in rat models by MRgFUS.

KW - Active targeting

KW - MRgFUS

KW - SPIO

KW - Synergistic agents

UR - http://www.scopus.com/inward/record.url?scp=85014458860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014458860&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2017.02.037

DO - 10.1016/j.biomaterials.2017.02.037

M3 - Article

C2 - 28279919

AN - SCOPUS:85014458860

VL - 127

SP - 25

EP - 35

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -